Organization (Industry)
ROCKET PHARMACEUTICALS, INC.
ClinicalTrials.gov lists ROCKET PHARMACEUTICALS, INC. as lead sponsor of 19 trials. It has 16 active development programs and 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 4 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers ROCKET PHARMACEUTICALS, INC.: 19 lead-sponsored trials and 1 legal-entity registration.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (23)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Cardiomyopathies | 9 |
| Anemia | 6 |
| Glycogen Storage Disease Type IIb | 5 |
| Intellectual Disability | 5 |
| Fanconi Syndrome | 4 |
Showing 5 of 23 disease areas.
Trials by start year as sponsor or collaborator (13)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2023 | 3 |
| 2022 | 3 |
| 2020 | 4 |
| 2019 | 5 |
| 2018 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2013 | 1 |
| 2012 | 1 |
Showing 10 of 13 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 14 months across 10 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (16)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| RP-L102 | Anemia | Phase 2 | 3 |
| RP-L102 | Fanconi Syndrome | Phase 2 | 3 |
| RP-A501 | Cardiomyopathy, Hypertrophic | Phase 2 | 2 |
| RP-A501 | Intellectual Disability | Phase 2 | 2 |
| RP-A501 | Aortic Valve Stenosis | Phase 2 | 2 |
Showing 5 of 16 active programs.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Timolol | 1 |
| Co-Latanoprost | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 38% hit target (n=8) | 20% on time (n=5) |
Journals published in (13)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Cardiovascular research | 2 |
| The New England journal of medicine | 2 |
| British journal of pharmacology | 1 |
| Circulation research | 1 |
| Current vascular pharmacology | 1 |
Showing 5 of 13 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 42 | 0 | 2020-07-07 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 0 | -223,123,000 | 142,015,000 |
| 2024 | 0 | -258,746,000 | 171,244,000 |
| 2023 | 0 | -245,595,000 | 186,342,000 |
| 2022 | 0 | -221,863,000 | 165,570,000 |
| 2021 | 0 | -169,069,000 | 125,476,000 |
| 2020 | 0 | -139,700,000 | 105,438,000 |
| 2019 | 0 | -77,270,000 | 57,907,000 |
| 2018 | 0 | -74,518,000 | 53,270,000 |
| 2017 | 0 | -19,578,000 | 14,917,000 |
| 2016 | 0 | -7,573,000 | 5,994,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (31)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-06-10 | Other financing | 180,000,000 | Sec extracted |
| 2026-04-26 | Royalty / licensing | 180,000,000 | Sec extracted |
| 2026-03-10 | Other financing | not disclosed | Edgar offerings |
| 2026-03-10 | ATM offering | not disclosed | Sec extracted |
| 2025-07-07 | Other financing | not disclosed | Sec extracted |
Showing 5 of 31 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 1 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (4)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Fred Hutch Cancer Center | Co sponsors trial with | 1 |
| University of California System | Co sponsors trial with | 1 |
| Government of the United States of America | Co sponsors trial with | 1 |
| California Institute for Regenerative Medicine | Co sponsors trial with | 1 |
Latest dated events (104)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-10 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-26 | Royalty / licensing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-04-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 104 events.
Biomarker capability evidence (59)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BAG3 | Trial sponsor | Named in trial inclusion criteria |
| BAG3 | Trial sponsor | Named in trial inclusion criteria |
| CD34 | Trial sponsor | Named in trial inclusion criteria |
| CD34 | Trial sponsor | Named in trial inclusion criteria |
| CD34 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 59 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.